Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H14N2.ClH |
Molecular Weight | 186.682 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(CNN)C1=CC=CC=C1
InChI
InChIKey=VATMJXRAQUGDSQ-UHFFFAOYSA-N
InChI=1S/C9H14N2.ClH/c1-8(7-11-10)9-5-3-2-4-6-9;/h2-6,8,11H,7,10H2,1H3;1H
PHENIPRAZINE is a monoamine oxidase inhibitor of the hydrazine chemical class that was used for the treatment of depression, schizophrenia, and also as a long-acting coronary vasodilator in patients suffering from angina pectoris. PHENIPRAZINE was discontinued due to toxicity concerns such as jaundice, amblyopia, and optic neuritis.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
9 mg 1 times / day multiple, oral Recommended Dose: 9 mg, 1 times / day Route: oral Route: multiple Dose: 9 mg, 1 times / day Sources: |
unhealthy, 50 n = 1 Health Status: unhealthy Condition: Depression Age Group: 50 Sex: M Population Size: 1 Sources: |
Disc. AE: Amblyopia... AEs leading to discontinuation/dose reduction: Amblyopia Sources: |
18 mg 1 times / day multiple, oral (max) Studied dose Dose: 18 mg, 1 times / day Route: oral Route: multiple Dose: 18 mg, 1 times / day Sources: Page: p.1959 |
unhealthy, 65 n = 1 Health Status: unhealthy Condition: Hypertension Age Group: 65 Sex: F Population Size: 1 Sources: Page: p.1959 |
Disc. AE: Hepatotoxicity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (grade 5) Sources: Page: p.1959 |
25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Disc. AE: Blurred vision, Scotoma... AEs leading to discontinuation/dose reduction: Blurred vision Sources: Page: p.2Scotoma Ataxia Weakness in extremity |
25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Disc. AE: Maculo-papular rash, Blurred vision... AEs leading to discontinuation/dose reduction: Maculo-papular rash Sources: Page: p.2Blurred vision |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Amblyopia | Disc. AE | 9 mg 1 times / day multiple, oral Recommended Dose: 9 mg, 1 times / day Route: oral Route: multiple Dose: 9 mg, 1 times / day Sources: |
unhealthy, 50 n = 1 Health Status: unhealthy Condition: Depression Age Group: 50 Sex: M Population Size: 1 Sources: |
Hepatotoxicity | grade 5 Disc. AE |
18 mg 1 times / day multiple, oral (max) Studied dose Dose: 18 mg, 1 times / day Route: oral Route: multiple Dose: 18 mg, 1 times / day Sources: Page: p.1959 |
unhealthy, 65 n = 1 Health Status: unhealthy Condition: Hypertension Age Group: 65 Sex: F Population Size: 1 Sources: Page: p.1959 |
Ataxia | Disc. AE | 25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Blurred vision | Disc. AE | 25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Scotoma | Disc. AE | 25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Weakness in extremity | Disc. AE | 25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Blurred vision | Disc. AE | 25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Maculo-papular rash | Disc. AE | 25 mg 1 times / day multiple, oral Highest studied dose Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: Page: p.2 |
unhealthy n = 1 Health Status: unhealthy Condition: Depression Population Size: 1 Sources: Page: p.2 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C667
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m882
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT001273
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
CHEMBL22498
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
78085
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
54779-57-6
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
SUPERSEDED | |||
|
5B3OM8452C
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
15573-15-6
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C73612
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
17766
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
6182
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
66-05-7
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY | |||
|
DTXSID8021149
Created by
admin on Fri Dec 15 16:26:50 GMT 2023 , Edited by admin on Fri Dec 15 16:26:50 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD